StemCell Therapy

Signal Genetics (NASDAQ: MGEN) and BioTelemetry (NASDAQ:BEAT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Signal Genetics and BioTelemetrys net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Signal Genetics and BioTelemetrys top-line revenue, earnings per share and valuation.

BioTelemetry has higher revenue and earnings than Signal Genetics.

Insider and Institutional Ownership

16.5% of Signal Genetics shares are owned by institutional investors. Comparatively, 76.7% of BioTelemetry shares are owned by institutional investors. 44.4% of Signal Genetics shares are owned by company insiders. Comparatively, 9.6% of BioTelemetry shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Signal Genetics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500. Comparatively, BioTelemetry has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Signal Genetics and BioTelemetry, as provided by MarketBeat.com.

Signal Genetics currently has a consensus price target of $23.00, suggesting a potential upside of 179.81%. BioTelemetry has a consensus price target of $45.75, suggesting a potential upside of 28.87%. Given Signal Genetics higher probable upside, equities analysts plainly believe Signal Genetics is more favorable than BioTelemetry.

Summary

BioTelemetry beats Signal Genetics on 7 of the 11 factors compared between the two stocks.

About Signal Genetics

Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Companys diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individuals long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Companys MyPRS test provides a whole-genomic expression profile of a patients multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

About BioTelemetry

BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segments principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Companys research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).

Receive News & Ratings for Signal Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signal Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
Head to Head Survey: Signal Genetics (MGEN) & BioTelemetry (BEAT) - TrueBlueTribune

This entry was posted on August 26, 2017 at 1:41 pm and is filed under Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |